Novel compounds-300
AssigneeAstraZeneca AB
InventorsYun-Xing Cheng, Vijayaratnam Santhakumar, Miroslaw Jerzy Tomaszewski
Life of this patent
Estimating the term…
Abstract
Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, m, n, q, s, t, X, and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
Claims23
A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomer, enantiomer, or mixture thereof:
- wherein
- each R1 is independently selected from fluoro, C3-7cycloalkyl, C1-7alkyl, C2-6alkenyl, C2-6alkynyl, C1-7alkoxy, C3-7cycloalkoxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl, C2-6alkenyloxy-C1-6alkyl, C2-6alkynyloxy, C2-6alkynyloxy-C1-6alkyl, C1-6alkylamino, di-C1-6alkylamino, C3-7heterocycloalkyloxy, C3-7heterocycloalkyl, C6-10aryl-C1-3alkoxy, C6-10aryl-C1-3alkyl, C3-9heteroaryl-C1-3alkoxy, C3-9heteroaryl-C1-3alkyl, C3-7heterocycloalkyl-C1-3alkoxy, C3-7heterocycloalkyl-C1-3alkyl, C3-7cycloalkyloxy, C3-7cycloalkyl-C1-3alkyl, C3-7cycloalkyl-C1-3alkoxy and C3-7cycloalkyl-C1-3alkoxy-C1-3alkyl, wherein said C3-7cycloalkyl, C1-7alkyl, C2-6alkenyl, C2-6alkynyl, C1-7alkoxy, C3-7cycloalkoxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl, C2-6alkenyloxy, C2-6alkenyloxy-C1-6alkyl, C2-6alkynyloxy, C2-6alkynyloxy-C1-6alkyl, C1-6alkylamino, di-C1-6alkylamino, C3-7heterocycloalkyloxy, C3-7heterocycloalkyl, C6-10aryl-C1-3alkoxy, C6-10aryl-C1-3alkyl, C3-9heteroaryl-C1-3alkoxy, C3-9heteroaryl-C1-3alkyl, C3-7heterocycloalkyl-C1-3alkoxy, C3-7heterocycloalkyl-C1-3alkyl, C3-7cycloalkyloxy, C3-7cycloalkyl-C1-3alkyl, C3-7cycloalkyl-C1-3alkoxy and C3-7cycloalkyl-C1-3alkoxy-C1-3alkyl are optionally substituted with one or more group selected from phenyl, C3-6cycloalkyl, C2-5heterocycloalkyl, C3-5heteroaryl, —CN, —SR, —OR, —O(CH2)p—OR, R, —C(═O)—R, —CO2R, —SO2R, —SO2NRR′, halogen, —NO2, —NRR′, —(CH2)pNRR′, and —C(═O)—NRR;
- each R2 is independently selected from halogen, C1-6alkyl, C3-7cycloalkyl, halogenated C1-6alkyl, C1-6alkoxy, and halogenated C1-6alkoxy;
- each R3 is independently selected from halogen, C1-6alkyl, C3-7cycloalkyl, halogenated C1-6alkyl, CN, C1-6alkoxy, and halogenated C1-6alkoxy;
- or two R3 together form a C1-6alkylene, C1-6alkylenoxy, or halogenated C1-6alkylene;
- R4 is hydrogen, C1-6 alkyl, or C1-6 haloalkyl;
- q is 1, 2, 3 or 4;
- p is 2, 3 or 4;
- s is 0, 1, 2, 3, or 4;
- t is 0, 1, 2, 3, or 4;
- n is 0, 1, 2, 3 or 4;
- m is 0, 1, 2, 3 or 4;
- Y is —CR5R6—, —O—, or —S—;
- X is —CR5R6—, —NR7—, —O—, or —S—;
- each R5, R6 and R7 are independently selected from hydrogen, C1-6alkyl, C2-6alkenyl and halogenated C1-6alkyl;
- and
- each R and R′ are independently C1-6alkyl, C2-6alkenyl or halogenated C1-6alkyl, with a proviso that at least one of X and Y is —CR5R6—, with a further proviso that the compound is not (4aS,8aS)-4-(1-(4-(ethoxymethyl)-1-methylcyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one.
8-14. (canceled)
A compound selected from
- (4aR,8aS)-1-(1-(4-(propoxymethyl)cyclohexyl)piperidin-4-yl)octahydroquinazolin-2(H)-one;
- (4aR,8aS)-1-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1H)-one;
- (4aR,8aS)-1-(1-(4-propoxycyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1 H)-one;
- (4aR,8aS)-1-(1-(4-isopropoxycyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1 H)-one;
- (4aR,8aS)-1-(1-(4-(ethoxymethyl)cyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1 H)-one;
- (4aR,8aS)-1-(1-(4-(prop-2-ynyloxy)cyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1H)-one;
- (4aR,8aS)-1-(1-cyclopentylpiperidin-4-yl)octahydroquinazolin-2(1 H)-one;
- (4aR,8aS)-1-(1-(4-ethylcyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1H)-one;
- (4aR,8aS)-1-(1-cyclohexylpiperidin-4-yl)octahydroquinazolin-2(1 H)-one;
- (4aS ,8aS)-4-(1-(4-(ethoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-4-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-4-(1-(4-propoxycyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-4-(1-(4-(cyclopropylmethoxy)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(4-((cyclopropylmethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(4-((2-fluoroethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(4-((2,2-difluoroethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-4-(1-(4-((cyclobutylmethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(4-(ethoxymethyl)-4-methylcyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aR,8aR)-4-(1-((1s,4S)-4-((cyclopropylmethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (cis)-4-(1-((1s,4S)-4-(ethoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aR,8aR)-6,6-difluoro-4-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-6,6-difluoro-4-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(3-(ethoxymethyl)cyclobutyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-4-(1-(3-((cyclobutylmethoxy)methyl)cyclobutyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(3-((cyclopropylmethoxy)methyl)cyclobutyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,8aS)-4-(1-((1R,3S)-3-(ethoxymethyl)cyclopentyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-((S ,3R)-3-(ethoxymethyl)cyclopentyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS ,8aS)-4-(1-(3-(ethoxymethyl)cyclopentyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aR,8aR)-4-(1-((1R,3S)-3-(ethoxymethyl)cyclopentyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (4aS,7aR)-4-(1-((1s,4R)-4-((cyclopropylmethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one;
- 4-(1-((1s,4R)-4-((cyclopropylmethoxy)methyl)cyclohexyl)piperidin-4-yl)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one;
- (4aR,8aS)-1-(1-(4-((2,2-difluoroethoxy)methyl)cyclohexyl)piperidin-4-yl)octahydroquinazolin-2(1 H)-one;
- enantiomers thereof, diastereomers thereof, pharmaceutically acceptable salts thereof, and mixtures thereof.
(4aS,8aS)-6,6-difluoro-4-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one, a diastereomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof
(4aS,8aS)-6,6-difluoro-4-(1-((1R,4S)-4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one, a pharmaceutically acceptable salt thereof, or a mixture thereof.
(4aS,8aS)-6,6-difluoro-4-(1-((14S,4S)-4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one, a pharmaceutically acceptable salt thereof, or a mixture thereof.
Diastereomer 2 of (4aS,8aS)-6,6-difluoro-4-(l -(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one as prepared in Example 38, a pharmaceutically acceptable salt thereof, or a mixture thereof.
Diastereomer 1 of (4aS,8aS)-6,6-difluoro-4-(1-(4-(isopropoxymethyl)cyclohexyl)piperidin-4-yl)hexahydro-2H-benzo[b][1,4]oxazin-3(4H)-one as prepared in Example 38, a pharmaceutically acceptable salt thereof, or a mixture thereof.
21-24. (canceled)
27-30. (canceled)
A process for preparing a compound of Formula I, comprising:
- reacting a compound of Formula II with a compound of
- wherein
- each R′ is independently selected from fluoro, C3-7cycloalkyl, C1-7alkyl, C2-6alkenyl, C2-6alkynyl, C1-7alkoxy, C3-7cycloalkoxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl, C2-6alkenyloxy, C2-6alkenyloxy-C1-6alkyl, C2-6alkynyloxy, C2-6alkynyloxy-C1-6alkyl, C1-6alkylamino, di-C1-6alkylamino, C3-7heterocycloalkyloxy, C3-7heterocycloalkyl, C6-10aryl-C1-3alkoxy, C6-10aryl-C1-3alkyl, C3-9heteroaryl-C1-3alkoxy, C3-9heteroaryl-C1-3alkyl, C3-7heterocycloalkyl-C1-3alkoxy, C3-7heterocycloalkyl-C1-3alkyl, C3-7cycloalkyloxy, C3-7cycloalkyl-C1-3alkyl, C3-7cycloalkyl-C1-3alkoxy and C3-7cycloalkyl-C1-3alkoxy-C1-3alkyl, wherein said C3-7cycloalkyl, C1-7alkyl, C2-6alkenyl, C2-6alkynyl, C1-7alkoxy, C3-7cycloalkoxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl, C2-6alkenyloxy, C2-6alkenyloxy-C1-6alkyl, C2-6alkynyloxy, C2-6alkynyloxy-C1-6alkyl, C1-6alkylamino, di-CC1-6alkylamino, C3-7heterocycloalkyloxy, C3-7heterocycloalkyl, C6-10aryl-C1-3alkoxy, C6-10aryl-C1-3alkyl, C3-9heteroaryl-C1-3alkoxy, C3-9heteroaryl-C1-3alkyl, C3-7heterocycloalkyl-C1-3alkoxy, C3-7heterocycloalkyl-C1-3alkyl, C3-7cycloalkyloxy, C3-7cycloalkyl-C1-3alkyl, C3-7cycloalkyl-C1-3alkoxy and C3-7cycloalkyl-C1-3alkoxy-C1-3alkyl are optionally substituted with one or more group selected from phenyl, C3-6cycloalkyl, C2-5heterocycloalkyl, C3-5heteroaryl, —CN, —SR, —OR, —O(CH2)p—OR, R, —C(═O)—R, —CO2R, —SO2R, —SO2NRR′, halogen, —NO2, —NRR′, —(CH2)pNRR′, and —C(═O)—NRR′;
- each R2 is independently selected from halogen, C1-6alkyl, C3-7cycloalkyl, halogenated C1-6alkyl, C1-6alkoxy, and halogenated C1-6alkoxy;
- each R3 is independently selected from halogen, C1-6alkyl, C3-7cycloalkyl, halogenated C1-6alkyl, CN, C1-6alkoxy, and halogenated C1-6alkoxy;
- or two R3 together form a C1-6alkylene, C1-6alkylenoxy, or halogenated C1-6alkylene;
- R4 is hydrogen, C1-6 alkyl, or C1-6 haloalkyl;
- q is 1, 2, 3 or 4;
- p is 2, 3 or 4;
- s is 0, 1, 2, 3, or 4;
- t is 0, 1, 2, 3, or 4;
- n is 0,1, 2, 3 or 4;
- m is 0, 1, 2, 3 or 4;
- Y is —CR5R6—, —O—, or —S—;
- X is —CR5R6—, —NR7—, —O—, or —S—;
- each R5, R6 and R7 are independently selected from hydrogen, C1-6alkyl, C2-6alkenyl and halogenated C1-6alkyl;
- and
- each R and R′ are independently C1-6alkyl, C2-6alkenyl or halogenated C1-6alkyl, with a proviso that at least one of X and Y is —CR5R6—.
Dependencies are inferred from the claim text.